All In Biotech

Drug Trial Radar · NCT07215390

A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio

A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneration

Last checked: Nov 19, 2026Latest source record: Jun 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 240 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

240

Planned (sponsor's estimate)

Start

Jun 23, 2025

Primary completion

Jun 25, 2027

Study completion Nov 2027

Sponsor

Lead sponsor
Apellis Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Oct 10, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase 2, Randomized, Placebo-controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL-3007 in Combination with Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed with Geographic Atrophy Secondary to Age-Related Macular Degeneration

Conditions

  • Geographic Atrophy Secondary to Age-related Macular Degeneration

Interventions

  • APL-3007, pegcetacoplan (APL-2)Drug

    Complement C3 inhibitor

  • APL-3007, pegcetacoplan (APL-2)Drug

    Complement C3 Inhibitor

  • Placebo, SyfovreOther

    Complement C3 Inhibitor

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline (CFB) in the area of artificial intelligence (AI)-based SD-OCT assessment of RPE lesion in the study eyeTime frame: At month 12

Locations

78 sites in 1 country. Site status is shown where the registry gives one.

  • Associated Retina Consultants (01065)

    Gilbert, Arizona · Recruiting

  • Barnet Dulaney Perkins Eye Center (01018)

    Mesa, Arizona · Recruiting

  • Associated Retina Consultants - Phoenix

    Phoenix, Arizona · Recruiting

  • Retinal Research Institute, LLC (01021)

    Phoenix, Arizona · Recruiting

  • Research Network Arizona

    Scottsdale, Arizona · Recruiting

  • California Retina Consultants (CRC) - Bakersfield Office

    Bakersfield, California · Recruiting

  • Retinal Diagnostic Center

    Campbell, California · Recruiting

  • The Retina Partners - Encino

    Encino, California · Recruiting

  • Retina Consultants of Orange County - Fullerton Office

    Fullerton, California · Recruiting

  • Salehi Retina Institute, Inc dba Retina Associate or Southern California (01034)

    Huntington Beach, California · Recruiting

  • Salehi Retina Institute, Inc. Dba Retina Associates of Southern California (01034)

    Huntington Beach, California · Recruiting

  • California Retina Consultants (01054)

    Oxnard, California · Recruiting

  • Retina Consultants San Diego

    Poway, California · Recruiting

  • Orange County Retina Medical Group

    Santa Ana, California · Recruiting

  • Retina Macula Institute

    Torrance, California · Recruiting

  • Bay Area Retina Associates - Walnut Creek

    Walnut Creek, California · Recruiting

  • Colorado Retina Associates, PLLC

    Lakewood, Colorado · Recruiting

  • Advanced Vision Research Institute

    Longmont, Colorado · Recruiting

  • Connecticut Eye Consultants, PC (01074)

    Danbury, Connecticut · Recruiting

  • ClearVista Clinical Research, LLC (01096)

    Bayonet Point, Florida · Recruiting

  • Advance Retina Institute

    Bonita Springs, Florida · Recruiting

  • Florida Retina Institute (01053)

    Orlando, Florida · Recruiting

  • Florida Retina Institute - Orlando (01053)

    Orlando, Florida · Recruiting

  • Retina Specialty Institute - Pensacola

    Pensacola, Florida · Recruiting

  • Eye Associates of Pinellas (01020)

    Pinellas Park, Florida · Recruiting

  • Retina Vitreous Associates of Florida (RVA) - Saint Petersburg

    St. Petersburg, Florida · Recruiting

  • Retina Vitreous Associates of Florida

    Tampa, Florida · Recruiting

  • Center for Retina and Macular Disease (01026)

    Winter Haven, Florida · Recruiting

  • Southeast Retina Center

    Augusta, Georgia · Recruiting

  • Illinois Retina Associates, S.C. - Oak Park (01061)

    Oak Park, Illinois · Recruiting

  • Midwest Eye Institute (01066)

    Carmel, Indiana · Recruiting

  • Vision Research Solutions

    Indianapolis, Indiana · Recruiting

  • Advancing Research International. LLC (01090)

    Indianapolis, Indiana · Recruiting

  • Retina Consultants P.C.

    Indianapolis, Indiana · Recruiting

  • Retina Associates New Orleans - Jefferson Parish Location

    Metairie, Louisiana · Recruiting

  • The Retina Care Center

    Baltimore, Maryland · Recruiting

  • The Retina Group of Washington (01089)

    Chevy Chase, Maryland · Recruiting

  • Cumberland Valley Retina Consultants (CVRC)

    Hagerstown, Maryland · Recruiting

  • Retina Specialists

    Towson, Maryland · Recruiting

  • Mississippi Retina Associates

    Madison, Mississippi · Recruiting

Showing 40 of 78 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.